SEC Form 4 · accession 0001213900-17-007160
ORAMED PHARMACEUTICALS INC. · ORMP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Nadav Kidron
Officer — President and CEO · Director · 10% Owner
Period of report
Jun 30, 2017
Accepted (ET)
Jul 5, 2017 · 3:40 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001176309
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $7.77 | Jun 30, 2017 | A | 147,000 | A | — | Jun 30, 2027 | Common Stock | 147,000 | 147,000 | D |
Explanation of responses
- F1The Stock Option will vest in 3 equal installments of 49,000 on each of December 31, 2017, December 31, 2018 and December 31, 2019, subject to the company share price reaching the target of $8.0, $9.5 and $12.5 per share, respectively.